Abstract: The invention relates to novel compounds derived from pentaerythrite compounds of formula (XII) and (XVI), which can be used as pharmaceutically active substances, specially in the treatment of cardiac and circulatory diseases.

Abstract: The invention describes novel compounds derived from pentaerythritol of general formula I, XIV, XVI, XIX and XXII, the substituents being as defined in the description, which can be used as pharmaceutical active substances, especially for the treatment of cardiovascular diseases.

Abstract: The present invention describes the use of nitric-oxide-liberating or transferring compounds, stimulators of endogenous NO formation, as well as stimulators of guanylate cyclase, for prevention, treatment and elimination of endothelial dysfunctions and the diseases accompanying these dysfunctions or caused by them, as well as the use of said compounds to produce pharmaceutical products for the cited areas of application.

Abstract: An orally administrable drug formulation containing levodopa and carbidopa, and having a short release time, is disclosed. The formulation is useful in the treatment of Parkinson's disease.

Abstract: A drug formulation administrable by mouth for the treatment of central dopamine deficiency condition, said formulation comprising100 to 250 parts by weight of levodopa,10 to 25 parts by weight of carbidopa,a polymer mixture in an amount of 10 to 200% based on said drugs, said polymer mixture consisting of:0 to 100 parts by weight of a completely saponified polyvinyl alcohol having 0 to 3% residual acetyl content, a mean molecular weight of 60,000 to 80,000 and a total surface area of 0.1 m.sup.2 /g to 0.18 m.sup.2 /g, and0 to 100 parts weight of a partially saponified polyvinyl alcohol having 10 to 18% residual acetyl content, a mean molecular weight of 80,000, a total surface area of 0.5 m.sup.2 /g to 0.69 m.sup.2 /g, and a specific pore volume of 0.2 cm.sup.3 /g to 0.36 cm.sup.3 /g,and an effective amount of customary galenic adjuvants.